New coronavirus test unveiled at Medlab Middle East

A ground-breaking test for the potentially fatal 2019-nCoV strain of coronavirus is in the final stages of development at global health diagnostics company Randox Laboratories. The soon-to-be-launched test, developed on Randox’s patented Biochip Technology, will be available for immediate 2019-nCoV testing, but an additional enhanced multiplex array will also include tests for other respiratory viruses which can display the same symptoms. The new enhanced Biochip will therefore allow clinicians quickly and efficiently to differentiate between potentially lethal and non-lethal infections.

On the alert for coronavirus: the role of biomedical science

Public Health England has issued guidelines for hospital laboratories in case coronavirus infection arrives in the UK. Public fears are growing, but biomedical scientists who specialise in viruses and viral diseases are prepared should cases reach their hospitals.

Monoclonal antibodies to coronaviruses

Coronaviruses are RNA viruses that infect many animal species. In humans they usually cause mild respiratory disease similar to the common cold. However, two recent outbreaks of acute respiratory illness have occurred; severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These coronaviruses both caused severe illness with high mortality rates.